Introduction
Neuromodulatory devices offer additional treatment options to refractory pharmacologic intervention for the treatment of chronic cluster headaches (CH). Clinical experience suggests vagus nerve stimulation (VNS) may be beneficial; however, inherent risks are associated with surgical implantation. As such, a need for the development of a non-invasive VNS (nVNS) modality exists.
Aim
Evaluate the long-term effects of an nVNS device (gammaCore ® ) in the extension phase of the Prevention and Acute (PREVA) Treatment of Chronic Cluster Headache study.
Methods
This randomized, controlled study consisted of a 2-week run-in phase, followed by a 4-week randomized (1:1; nVNS vs standard of care [SoC] ) phase, and a 4-week extension phase. During the extension phase, subjects delivered 3 consecutive 90-second stimulations prophylactically twice daily (mandatory, right side only) and optionally at the onset of a CH attack (2 stimulations on headache side, 1 on opposite side) for rescue treatment. Efficacy end points evaluated in the extension phase were mean number of all CH attacks, pain intensity (range: no pain to very severe pain), treatment success rate, and use of rescue medication. Safety was assessed by monitoring the frequency of adverse events.
Results
A total of 97 subjects, across 10 European sites, were randomized to treatment; 90 entered the extension phase. All data has been collected and will be available for presentation at EHMTIC.
Conclusion
Findings from PREVA are expected to provide further evidence of the sustained clinical effects and continued safety of nVNS in the treatment of chronic CH.
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